AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06644313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebreltinib
Description: Neoadjuvant treatment stage: Vebreltinib 200mg, bid, po, 2-4 months in total; Surgical treatment stage: CR + PR patients and SD + PD patients who could still undergo surgery will receive radical surgery; Adjuvant treatment stage: CR, PR and SD patients who have been treated surgically: Vebreltinib 200mg, bid, po, up to 2 years/until the disease progressed. PD patients: transferred into medical oncology or/and radiation oncology and receive comprehensive therapy.
Study NCT04981145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod Tablets
Description: Participants are treated with Iguratimod Tablets 25 mg Twice a day for 24 weeks.
Study NCT04981145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Participants are treated with Hydroxychloroquine Sulfate Tablets 200 mg Twice a day for 24 weeks.
Study NCT06184269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1017-1
Description: One tablet administered alone
Study NCT06184269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1017-1A
Description: One tablet administered alone
Study NCT06184269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BR1017-1B
Description: One tablet administered alone
Study NCT05689099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 1.34 mg/mL
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Study NCT05689099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide B, 0.68 mg/mL
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
Study NCT06469242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A multifocal contact lenses
Description: Investigational multifocal soft contact lenses
Study NCT06469242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A multifocal contact lenses
Description: Commercially available multifocal soft contact lenses
Study NCT06469242 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE® Cleaning & Disinfecting Solution
Description: Hydrogen peroxide-based contact lens cleaning and disinfection system
Study NCT06296225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration
Description: Grip strenght measurement will always be done in the same way : for each series, 3 measurements of maximum strength will be taken for each side. Participants will receive verbal encouragement.~After initial both sides grip strength evaluation, all participant will first experiment the vibration situation using the device Vibramoov Physio (TechnoConcept, Manosque, France): the vibrations had a frequency of 100Hz, with an amplitude of 2mm, they will be applied to the anterior part of the forearm for 10 minutes, 3 times. At the end of each 10 minutes vibration session, handgrip strength will be assessed.~* Participants then have a one-hour rest period.~* Control situation: participants will have 4 series of grip strength measurements every 10 minutes.~At the end of the 2 hours, the patient will be discharged from the study protocol.
Study NCT05941429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-Silver Fluoride
Description: NSF is a varnish which has been introduced as experimental formulation . the laboratory synthesis of NSF was carried out in a nano techonolgy center .
Study NCT05941429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: 38% silver diamine fluoride
Study NCT06636006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 50 continuous minutes, at moderate intensity (Identified by the Borg Subjective Perception of Exertion Scale, scores from 12 to 13)
Study NCT06636006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: CBT-I includes some therapies, including sleep restriction therapy, stimulus control therapy, sleep hygiene education, relaxation and cognitive therapy\[19\]. Traditionally, CBT-I is applied in person (individually or in a group) by a trained psychologist or psychiatrist. However, several studies show similar effects when CBT-I is performed remotely, and online (digital)
Study NCT06271057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: golcadomide
Description: golcadomide 0.3 mg weekly from D+5 post CAR T-cells administration until D+166
Study NCT05913908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUO Transcatheter Tricuspid Coaptation Valve System
Description: Reduction of tricuspid regurgitation through a transcatheter approach
Study NCT04695847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1231
Description: M1231 will be administered at escalated doses every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study NCT04695847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1231
Description: M1231 will be administered at the dose determined as RDE in part 1, every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
Study NCT06031480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and TQB2450
Description: Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent.
Study NCT06266416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA for Black Male Caregivers and Girls Empowerment
Description: IMAGE is delivered by trained Black female facilitators to improve girls' SRH outcomes, prevention HIV/STIs, and reduce sexual violence. Over the two days, some components of the curriculum are delivered separately to male caregivers and girls, covering parallel content, and other sections are delivered jointly in a single group. The curriculum, extensively tailored for the target population and pilot tested, addresses Black girls' sexual development, risk for sexual violence, female anatomy, body positivity, HIV/STI knowledge and attitudes, and condom use. IMAGE is designed to strengthen bonds and communication between male caregivers and girls by encouraging perspective-taking (i.e., reverse role play) and conflict resolution.
Study NCT06266416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-matched control program
Description: FUEL will engage Black male caregivers and girls to promote good nutrition, exercise, and informed consumer behavior. Topics include the impact of media on body image, evaluating nutritional labels to make healthy food choices, eating balanced meals, establishing regular exercise routines, and how families and communities can support healthy behavior. FUEL includes a brief video about HIV/AIDS and other STIs but otherwise does not otherwise address sexual health. Like IMAGE, FUEL is delivered in groups of 6-8 dyads over two workshop days (\~10 hours total) in one weekend. Parts of the curriculum are delivered separately to girls and male caregivers covering parallel content and other components are delivered jointly.
Study NCT06434727 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: Observational Study
Study NCT06046378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Story Group Prepared With Digital Audio File (Podcast)
Description: The students determined as a result of the randomization will be given a pre-test before the introduction to the Normal Birth and Postpartum Period  course, which is planned according to the academic calendar. Simultaneously with the subject, digital stories prepared with a digital audio file (podcast) will be sent to the students via e-mail and they will be listened to. At the end of the subject on the date planned according to the academic calendar, the students will be interviewed again and a questionnaire will be applied to evaluate the effectiveness of the digital stories prepared with the post-test and digital audio file (podcast). The retention test will be applied 21 days after the last test application.
Study NCT06046378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: After the students in the control group are determined, a pre-test will be conducted before the subject receives education. The same knowledge test will be repeated as a post-test after the students receive the classical course education and after the end of the subject. Students will be given a retention test 21 days after the last test. After the retention test application, digital stories prepared with a digital audio file (podcast) will be sent to the students in the control group. In this way, all students participating in the study will have access to the training material used in addition.
Study NCT05919498 — intervention group
Intervention type: OTHER
Intervention: Individual semi-directive interview
Description: This intervention concerns the trajectories of patients who have completed their participation in FASTRACS-RCT. Participant are : patients in the FASTRACS-RCT intervention arm (Groupe 1) and Trajectory persons (groupe 2).~During the individual interviews, the investigator and the participant will discuss the use of the FASTRACS-RCT tools and the patient's course of care.~The individual interviews will take place at the location chosen by the participant and will last on average one hour.
Study NCT05919498 — intervention group
Intervention type: OTHER
Intervention: Focus groups
Description: This second intervention will take place at the end of the last patient followed by the FASTRACS-RCT.~During the focus groups, participants will discuss the use of the FASTRACS-RCT tools.~The focus groups will take place in a meeting room made available for the occasion and will last on average two hours.
Study NCT05664529 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chatoor Feeding Scale
Description: Chatoor Feeding Scale will be used to evaluate mother infant relationship during feeding. Mothers will be asked to record a natural feeding session at home by video. The videos will be sent to the investigators by the parents. The first 20 minutes of the video will be evaluated for scoring.
Study NCT05974176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused CBT (TF-CBT)
Description: TF-CBT is an evidence-based treatment for children and adolescents impacted by trauma and their parents or caregivers. It is a components-based treatment model that incorporates trauma-sensitive interventions with cognitive behavioral, family, and humanistic principles and techniques.
Study NCT05974176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Systems therapy (TST)
Description: Trauma Systems Therapy (TST) is focused on the factors that contribute to children and adolescents who experience traumatic stress through the lens of the social context, vulnerabilities, and strengths of the person undergoing treatment.
Study NCT06231264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acustimulation at treatment sites
Description: A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.
Study NCT06231264 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous electrical acustimulation at sham sites
Description: A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.
Study NCT06563817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: All enrolled patients receive treatment with sirolimus (rapamycin)#The prescribed regimen involved a daily oral dosage of 1.5 mg for a duration of four weeks.
Study NCT05925465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary and mandibular nerve block
Description: receive bilateral combined maxillary and mandibular nerve block
Study NCT05925465 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: not receive any nerve block
Study NCT05254808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
Study NCT06504303 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed socket
Description: During the shape-capturing in-patient appointment, participants will be measured for the prosthetic device through (1) manual casting using Plaster of Paris bandages and (2) scanning using a 3D scanner. The clinician will manually modify the positive plaster cast and digitally modify the scanned impression using OMEGA software. The manually-modified positive cast will be digitized by scanning the cast, then 3D-printed. The digitally-modified socket file will also be 3D printed. The research investigator will make a de-identified mark on each socket to differentiate between the two sockets after 3D printing, and will record the order in which the sockets are fit to the patient.
Study NCT04855591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1703
Description: SHR-1703 will be administered subcutaneously
Study NCT04855591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo of SHR-1703 will be administered subcutaneously
Study NCT05822674 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin/metformin ( 50/500mg) Oral Tablet
Description: The drug was prescribed once daily per oral for 10 weeks
Study NCT05822674 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin/metformin(10/500mg) Oral Tablet
Description: The drug was prescribed once daily per oral for 10 weeks
Study NCT05254808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosfomycin
Description: Fosfomycin is a phosphoenolpyruvate (PEP) analogue that is produced by Streptomyces spp. It has a bactericidal action, primarily by inhibiting bacterial cell wall (peptidoglycan) synthesis. In the Netherlands, Fosfomycin is orally available as fosfomycin-trometamol (Monuril). Fosfomycin-trometamol is identical to fosfomycin-tromethamine. Fosfomycin-trometamol is a phosphoric acid derivative of fosfomycin, available in a single dose sachet containing white granules. One sachet contains 5.63 g of fosfomycin-trometamol, corresponding with 3000mg fosfomycin.
Study NCT05254808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Nitrofurantoin belongs to the group of nitrofuranes. Both nitrofurantoin and its metabolites have antibacterial activity, which is enhanced under acidic conditions. Nitrofurantoin is reduced to (active) metabolites by bacterial enzymes. These metabolites inhibit bacterial enzymes that are essential for energy metabolism and inhibit bacterial protein synthesis by binding to ribosomes. Active therapeutic concentrations are only reached in urine and not in other tissues. Several manufacturers produce generic nitrofurantoin in the solid oral form. Three different formulations exist: a macrocrystalized form, nitrofurantoin monohydrate (microcrystals) and a mixture of macrocrystals (75%) and monohydrate 25%) contained in a delayed-release gel matrix (Furabid®) In this trail only Furabid® will be used. Macrocrystals are slower dissolved and absorbed in comparison to the monohydrate.
Study NCT05089955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambient Experience
Description: MRI examination with Ambient Experience
Study NCT05317624 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: platelet rich plasma will be obtained from the particepants own blood mixed with activator and bupivacaine
Study NCT05317624 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1ml methyl prednisolone 40mg\\ml mixed with normal saline and bupivacaine
Study NCT04745884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive bilateral monitoring of ICP waveform
Description: Brain4care non-invasive bilateral monitoring of ICP waveform
Study NCT06327009 — intervention group
Intervention type: BEHAVIORAL
Intervention: fasting month of ramadan
Description: 100 patients with glomerulonephritis who decided to fast month of ramadan
Study NCT06419335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: The core component of this pilot study will be a single center open label randomized trial comparing low dose and high dose CoQ10 among 30 patients with Crohn's disease and fatigue (Cohort 1) and 15 healthy volunteers (Cohort 3).
Study NCT05255211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam tosilate
Description: IV before procedure
Study NCT05255211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: IV before procedure
Study NCT05615597 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Para-discal injection of corticoid
Description: In this pilot study, all patients underwent the same procedure: a corticosteroid infiltration via a para-discal approach. The infiltrations were performed under CT or scopy.
Study NCT05255211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: IV before procedure
Study NCT05683860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-004
Description: WVE-004 is a stereopure antisense oligonucleotide. It is administered via intrathecal injection
Study NCT04857151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App based mindfulness program (ABMP)
Description: App based mindfulness program (ABMP)
Study NCT05607563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM1009 injection
Description: Participants receive PM1009 intravenously, every 2 weeks
Study NCT05254418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dulaglutide injection
Description: All participants will undergo a 4-week run-in phase followed by 12 weeks of treatment (dulaglutide 1.5 mg/wk), followed by 4 weeks of follow up after discontinuing the study medication
Study NCT05887336 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Walther System
Description: Walther System providing INMEST treatment
Study NCT05887336 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Walther System
Description: Walther System not providing INMEST treatment, but otherwise behave as the active comparator.
Study NCT05887336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non preserved ocular lubricants
Description: * Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)
Study NCT05887336 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Non preserved ocular lubricants
Description: * Hyaluronic acid (HyloGel)~* Hyaluronic acid and Ectoin (Hylo Dual Intense)~* Hyaluronic acid and Trehalos (Theloz Duo)
Study NCT05887336 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eye lid procedure
Description: Lid hygiene, warm eye bag, lid massage and Omega 3
Study NCT05887336 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Eye lid procedure
Description: Lid hygiene, warm eye bag, lid massage and Omega 3
Study NCT06131112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 64Cu-DOTATATE PET/CT scan
Description: Patients in group A-C will have a 64Cu-DOTATATE PET/CT scan performed in addition to routine clinical procedures. Group D has had 64Cu-DOTATATE PET/CT performed as part of their clinical diagnostic work-up or follow-up; these data are retrospectively identified and included in the study, and group D will not be subject to any scans in the study.
Study NCT05913739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Therapy
Description: Nocturnal oxygen therapy minimum 6 hours
Study NCT06121544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma tau
Description: Plasma levels of different p-tau and np-tau species
Study NCT06121544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma Ab42/Ab40
Description: Plasma levels of Ab42/Ab40 ratio
Study NCT06121544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flutemetamol F18 Injection
Description: Positron emission tomography (PET) imaging of amyloid-β plaques
Study NCT06121544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: [18F]-RO6958948 Injection
Description: PET imaging of Tau aggregates
Study NCT06121544 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Different MRI sequences relevant for brain imaging